Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention

Ghenet K. Hagos, Samer O. Abdul-Hay, Johann Sohn, Praneeth D. Edirisinghe, R. Esala P. Chandrasena, Zhiqiang Wang, Qian Li and Gregory R. J. Thatcher
Molecular Pharmacology November 2008, 74 (5) 1381-1391; DOI: https://doi.org/10.1124/mol.108.046664
Ghenet K. Hagos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samer O. Abdul-Hay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johann Sohn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Praneeth D. Edirisinghe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Esala P. Chandrasena
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiqiang Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qian Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory R. J. Thatcher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown promise in colorectal cancer (CRC), but they are compromised by gastrotoxicity. NO-NSAIDs are hybrid nitrates conjugated to an NSAID designed to exploit the gastroprotective properties of NO bioactivity. The NO chimera ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094), a novel nitrate containing an NSAID and disulfide pharmacophores, is effective in vivo in rat models of CRC and is a lead compound for design of agents of use in CRC. Preferred chemopreventive agents possess 1) antiproliferative and 2) anti-inflammatory actions and 3) the ability to induce cytoprotective phase 2 enzymes. To determine the contribution of each pharmacophore to the biological activity of GT-094, these three biological activities were studied in vitro in compounds that deconstructed the structural elements of the lead GT-094. The anti-inflammatory and antiproliferative actions of GT-094 in vivo were recapitulated in vitro, and GT-094 was seen to induce phase 2 enzymes via the antioxidant responsive element. In the variety of colon, macrophage-like, and liver cell lines studied, the evidence from structure-activity relationships was that the disulfide structural element of GT-094 is the dominant contributor in vitro to the anti-inflammatory activity, antiproliferation, and enzyme induction. The results provide a direction for lead compound refinement. The evidence for a contribution from the NO mimetic activity of nitrates in vitro was equivocal, and combinations of nitrates with acetylsalicylic acid were inactive.

Footnotes

  • This research was funded in part by National Institutes of Health grants CA102590 and CA121107.

  • ABBREVIATIONS: CRC, colorectal cancer; ACF, aberrant crypt foci; AOM, azoxymethane; iNOS, inducible nitric-oxide synthase; NSAID nonsteroidal anti-inflammatory drug; ASA, aspirin; GI, gastrointestinal; NO-NSAID, NO-donating nonsteroidal anti-inflammatory drug; BECS, 1,2-bis-(2-ethoxycarbonylphenyl)sulfane; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; ARE, antioxidant responsive element; LPS, lipopolysaccharide; l-NAME, Nω-nitro-l-arginine methyl ester; CM, conditioned media; PBS, phosphate buffered saline; ERK, extracellular signal-regulated kinase; ERK, extracellular signal-regulated kinase; NQO1, NAD(P)H-dependent quinone oxidoreductase; CI, chemopreventive index; RT-PCR, reverse transcription-polymerase chain reaction; TNF, tumor necrosis factor; IL, interleukin; COX, cyclooxygenase; PG, prostaglandin; SPE/NO, spermine diazeniumdiolate salt; DETA/NO, diethyltriamine diazeniumdiolate; BF, 4′-bromoflavone; ISDN, isosorbide dinitrate; PTIO, 2-phenyl-4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide; CD, concentration required to double the specific activity of NAD(P)H-dependent quinone oxidoreductase; ODQ, 1H-[1,2,4]oxadiazolo[3,4-a]quinoxalin-1-one; MAPK, mitogen-activated protein kinase; PD 98059, 2′-amino-3′-methoxyflavone; GTN, nitroglycerin; DADS, dipropyl disulfide and diallyl disulfide; Keap1, protein Kelch-like ECH-associated protein 1; NCX 4016, 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; GT-947, ethyl 2-(1,3-bis(nitrooxy)propan-2-ylthio)benzoate; GT-794, ethyl 2-(2,3-bis(nitrooxy)propylthio)benzoate; GT-103, 2-((2,3-bis(nitrooxy)propylthio)carbonyl)phenyl acetate; GT-094, ethyl 2-((2,3-bis(nitrooxy)propyl)-disulfanyl)benzoate; GT-015, 3,3′-disulfanediylbis(propane-3,2,1-triyl) tetranitrate.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received February 23, 2008.
    • Accepted August 1, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 74 (5)
Molecular Pharmacology
Vol. 74, Issue 5
1 Nov 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention

Ghenet K. Hagos, Samer O. Abdul-Hay, Johann Sohn, Praneeth D. Edirisinghe, R. Esala P. Chandrasena, Zhiqiang Wang, Qian Li and Gregory R. J. Thatcher
Molecular Pharmacology November 1, 2008, 74 (5) 1381-1391; DOI: https://doi.org/10.1124/mol.108.046664

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention

Ghenet K. Hagos, Samer O. Abdul-Hay, Johann Sohn, Praneeth D. Edirisinghe, R. Esala P. Chandrasena, Zhiqiang Wang, Qian Li and Gregory R. J. Thatcher
Molecular Pharmacology November 1, 2008, 74 (5) 1381-1391; DOI: https://doi.org/10.1124/mol.108.046664
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics